Actuate Therapeutics

Manufacturing · Texas, United States · 11-50 Employees

View Company Info for Free

Overview

Headquarters

1751 River Run Ste 400, Fort Worth, Texa...

Phone Number

(817) 887-8455

Revenue

<$5 Million

Stock Symbol

ACTU

Industry

Manufacturing Pharmaceuticals Business Services Research & Development
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1

About Actuate Therapeutics

Actuate is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for cancers and inflammatory diseases. In addition to this randomized controlled study, Actuate is executing Phase 2 clinical trial for the treatment of myelofibrosis, a Phase 1/2 trial for neuroblastoma in pediatric patients, and a Phase 2 trial in salivary gland carcinomas. The company is also planning additional clinical studies of elraglusib in other cancers including studies for front line treatment of advanced pancreatic cancer both in combination with FOLFIRINOX, and with a checkpoint inhibitor containing regimen.Explore more
Actuate Therapeutics's Social MediaPopular SearchesActuate Therapeutics IncActuate TherapeuticsApotheca Therapeutics IncArcuate Therapeutics IncAcute Therapeutics IncSIC Code 28,283NAICS Code 32,325Ticker NASDAQ: ACTUShow more

Actuate Therapeutics Org Chart

Daniel Schmitt, President & Chief Executive Officer at Actuate Therapeutics
United States flag for contact location.

President & Chief Executive Officer

PhoneEmail
TS
United States flag for contact location.

Director, Clinical Operations

PhoneEmail
CK
United States flag for contact location.

Senior Director, Operations

PhoneEmail
AU
United States flag for contact location.

Senior Director, Clinical Science

PhoneEmail
KM
United States flag for contact location.

Associate Director, Quality & Safety

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.
SM
United States flag for contact location.

Senior Manager, Clinical Operations

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.

Is Actuate Therapeutics your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to Actuate Therapeutics

Compare insights from companies similar to Actuate Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

Actuate Therapeutics

<$5M
11-50
Public
$42.9M
2015
Daniel Schmitt, President & Chief Executive Officer at Actuate Therapeutics
Daniel SchmittPresident & CEO
$6.7M
11-50
Private
$74.8M
2006
N/A
<$5M
11-50
Private
-
2006
N/A
<$5M
11-50
Private
$18.4M
2007
BC
Bradley CarverCo-Founder & President, CEO & Chairman
<$5M
1-10
Private
-
2004
N/A
<$5M
1-10
Private
-
2000
SG
Stephan GlennVice President, Regulatory Affairs & Quality Assurance
<$5M
1-10
Private
$118.1M
2000
Illustration of an envelope

Company Profile Activity

i

Among all Manufacturing companies

Low Activity

High Activity

Activity Insights

Actuate Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.

What does this means?

Actuate Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Actuate Therapeutics.

Actuate Therapeutics financials insights

Gather financial insights about Actuate Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

2017

Private Equity

$3M

2018

Series A

$7M

2019

Series B

$28.2M

2025

Private Equity

$4.7M

See All Actuate Therapeutics's Financials Insights

Actuate Therapeutics Tech Stack

A closer look at the technologies used by Actuate Therapeutics

Most Recent Scoops

Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Actuate Therapeutics has reported that Elverglucib demonstrates minimal clinical risk with only two safety signals: temporary visual impairment (color blindness in the red spectrum lasting one hour to 24 hours post-infusion) and increased grade 3-4 neutropenia, both manageable with no intervention required for the visual effects.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Actuate Therapeutics has reported that Phase 2 trial demonstrated that patients completing at least one full cycle of Elverglucib plus gemcitabine achieved median overall survival of approximately 11 months compared to 7.2 months for gemcitabine alone, representing a hazard ratio of 0.5 and a 42% reduction in risk of death with nearly doubled one-year overall survival.
Medical Research, Pharmaceuticals, Clinical Operations, Finance, Risk
Project
Actuate Therapeutics has reported that lead compound Elverglucib has been credentialed preclinically in 18 different histologies across laboratories worldwide, with results published in scientific literature.
Medical Research, Pharmaceuticals
Project
Medical Research, Clinical Operations
See more scoops

Top Manufacturing Companies

Frequently Asked Questions Regarding Actuate Therapeutics

What is Actuate Therapeutics's stock symbol?
Actuate Therapeutics's stock symbol is ACTU
What is Actuate Therapeutics's official website?
Actuate Therapeutics's official website is www.actuatetherapeutics.com
What is Actuate Therapeutics's Revenue?
Actuate Therapeutics's revenue is <$5 Million
What is Actuate Therapeutics's SIC code?
Actuate Therapeutics's SIC: 28,283
What is Actuate Therapeutics's NAICS code?
Actuate Therapeutics's NAICS: 32,325
How many employees does Actuate Therapeutics have?
Actuate Therapeutics has 11-50 employees
What industry does Actuate Therapeutics belong to?
Actuate Therapeutics is in the industry of: Manufacturing, Pharmaceuticals, Business Services
What is Actuate Therapeutics competition?
Actuate Therapeutics top competitors include: IC-MedTech, SynDevRx, Novoclinica, Presidio Pharmaceuticals
What technology does Actuate Therapeutics use?
Some of the popular technologies that Actuate Therapeutics uses are: WooCommerce, WordPress.org, reCAPTCHA, PHP
How do I contact Actuate Therapeutics?
Actuate Therapeutics contact info: Phone number: (817) 887-8455 Website: www.actuatetherapeutics.com
What does Actuate Therapeutics do?

Actuate is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for cancers and inflammatory diseases. In addition to this randomized controlled study, Actuate is executing Phase 2 clinical trial for the treatment of myelofibrosis, a Phase 1/2 trial for neuroblastoma in pediatric patients, a... nd a Phase 2 trial in salivary gland carcinomas. The company is also planning additional clinical studies of elraglusib in other cancers including studies for front line treatment of advanced pancreatic cancer both in combination with FOLFIRINOX, and with a checkpoint inhibitor containing regimen.Read More

What are Actuate Therapeutics social media links?
Actuate Therapeutics Linkedin page Actuate Therapeutics Twitter page Actuate Therapeutics Facebook page
Who invested in Actuate Therapeutics?
Actuate Therapeutics has 7 investors including Kairos Ventures, DEFTA Partners, Bios Partners and Bios Partners.
Is Actuate Therapeutics a public company?
Yes, Actuate Therapeutics is a public company and is traded under the symbol ACTU
See more information about Actuate Therapeutics

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.